ArticleThe oncologist2026

Correction to: Phase I trial of SPH4336, a novel cyclin-dependent kinase 4/6 inhibitor, in patients with advanced solid tumors.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.